Monoparamunity inducers based on attenuated rabbit myxomaviruses

Abstract

The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals.

1 - 48 . (canceled) 
     
     
         49 . A method for regulating immune cells in a human patient comprising administering to the patient an inactivated, attenuated myxomavirus or a polypeptide or protein component thereof. 
     
     
         50 . The method of  claim 49 , comprising administering to the patient an inactivated, attenuated myxomavirus. 
     
     
         51 . The method of  claim 50 , wherein the attenuated myxomavirus is lyophilized. 
     
     
         52 . The method of  claim 50 , wherein the attenuated myxomavirus is inactivated with beta-propiolactone. 
     
     
         53 . The method of  claim 52 , wherein the beta-propiolactone is at a concentration of 0.01%-1%. 
     
     
         54 . The method of  claim 50 , wherein the attenuated myxomavirus is administered in tablet form. 
     
     
         55 . The method of  claim 54 , wherein the tablet is a buccal tablet. 
     
     
         56 . The method of  claim 51 , wherein the attenuated myxomavirus is inactivated with beta-propiolactone. 
     
     
         57 . The method of  claim 56 , wherein the beta-propiolactone is at a concentration of 0.01%-1%. 
     
     
         58 . The method of  claim 51 , wherein the attenuated myxomavirus is administered in tablet form. 
     
     
         59 . The method of  claim 58 , wherein the tablet is a buccal tablet. 
     
     
         60 . The method of  claim 49 , comprising administering to the patient a polypeptide or protein component of an attenuated myxomavirus. 
     
     
         61 . The method of  claim 60 , wherein the polypeptide or protein component is a viral envelope polypeptide or protein. 
     
     
         62 . The method of  claim 61 , wherein the viral envelope polypeptide or protein is an envelope cleavage product. 
     
     
         63 . The method of  claim 60 , wherein the polypeptide or protein component is a viral membrane or surface receptor. 
     
     
         64 . The method of  claim 60 , wherein the polypeptide or protein component is a native viral polypeptide or protein. 
     
     
         65 . The method of  claim 60 , wherein the polypeptide or protein component is a recombinant viral polypeptide or protein. 
     
     
         66 . The method of  claim 60 , wherein the polypeptide or protein component is administered in tablet form. 
     
     
         67 . The method of  claim 66 , wherein the tablet is a buccal tablet.